



## **The Effect of Extract of *U. Pilulifera* on Some Kidney Parameters of Diabetic Rats**

Saad Mutlaq Almutairi, Mohammed Hussain Alwadai, Badr Abdulrahman Alshehri, Abeer Mohammed Hosawi, Waleed Mashaal Alotaibi, Asrar Saad Jwuad Alanazi, Abullah Dakhel Alosimi, Rishaa Rashed Othman Aldajani  
*Ministry of Health, Saudi Arabia*

---

### **ABSTRACT**

*Diabetes is associated with health impacts and several organs are negatively affected by diabetes including kidneys. Various herbal remedies have been used to treat diabetes. *U. pilulifera* is one of herbal treatments for diabetes. The main objective of the present study is to investigate the therapeutic potential of *U. pilulifera* in offering kidney protection through assessment of urea, uric acid and creatinine. Methodology included collection of *U. pilulifera* and preparation of its extracts, induction of diabetic model and biochemical evaluation of urea, uric acid and creatinine tests. Study findings showed that levels of urea, uric acid and creatinine were significantly increased in diabetic group ( $P < 0.05$ ). Therapeutic options using the extract of *U. pilulifera* were able to significantly decrease the levels of urea, uric acid, and creatinine ( $P < 0.05$ ).*

*Taken together, experimental diabetic model showed negative impacts on kidney function tests urea, uric acid and creatinine. Using the extract of *U. pilulifera* showed significant restoring ability to restore kidney function tests to levels approximate to reference range. Taken together, the extract of *U. pilulifera* has a potential therapeutic option to be used in diabetic patients with renal impacts.*

**KEYWORDS:** diabetes, kidney function test, urea, uric acid, creatinine, *U. pilulifera*

---

### **I. INTRODUCTION**

Diabetes mellitus is viewed as chronic metabolic disorders with various impacts on human health from physical, psychological and social points of view. Furthermore, it is characterized by several metabolic disturbances including hyperglycemia, altered metabolism of lipids, carbohydrates and proteins<sup>11</sup>. According to study of Chauhan et al (2010), diabetes mellitus is considered the third “killer” of the health of human besides cancer, cardiovascular and cerebrovascular diseases. Epidemiological studies showed that there are more than 240 million diabetics worldwide of whom about 40% develop severe diabetic nephropathy.<sup>2</sup>

Several studies have revealed that diabetic experimental models including STZ models increased the levels of serum blood urea nitrogen (BUN) and serum uric acid.<sup>1,12</sup> It has also been reported that STZ displays nephrotoxic and hepatotoxic activity as well as necrosis of kidney tubules.<sup>8</sup>

Diabetic nephropathy (DN) leads to what is called asymptomatic kidney failure which may cause narrow and clogged glomerulus. Accordingly, waste products are not likely to be excreted which may lead to cytotoxicity.<sup>7</sup> Jonasson et al (1984) showed that diabetes leads to decreased nerve sensitivity manifested by

response to a filled bladder and the resulting pressure can cause deterioration to kidneys. Because of high sugar concentration, urinary tract infections are likely to occur.

Diabetic patients who developed kidney failure usually have bad choices including painful dialysis or kidney transplantation, both are costly and harmful.<sup>10</sup> Researchers have attempted to develop medications hoping to decline the progression of diabetic kidney damage with less side effects, but no significant outcome are reached.<sup>7</sup> According to this context, there has been a need to explore more therapeutic options in complementary and alternative medicine that may have potent antidiabetic as well as nephroprotective activity with fewer side effects.<sup>7</sup>

Several studies across literature have emphasized that diabetes is associated or lead to increased measures of urea, uric acid, and creatinine. These studies also pointed to the power of some herbal remedies known to have antidiabetic activities to ameliorate the impacts of diabetes through restoring the values of urea, uric acid, and creatinine to levels approximate to reference range.<sup>5,7,14</sup>

*Momordica dioica* was investigated for its effects as antidiabetic agent by Gupta et al (2011). Researchers reported nephroprotective effects of *Momordica dioica* in addition to restoring levels of urea, uric acid and creatinine. Similar findings have been obtained using *Olea europaea L* and *Gymnemamontanum*.<sup>5,14</sup> Another study by Basha et al (2011) pointed to protective effects Annona squamosa extract against diabetic STZ model.

In the present study, *Urtica pilulifera* was chosen to investigate the effects of its extract as an antidiabetic agent. The rational beyond selection of *U. pilulifera* is due to its involvement in folk medicine, and there is a need to investigate some of its chemical and pharmaceutical properties.

## II. STUDY OBJECTIVES

The main objective of the present study is to investigate the therapeutic potential of *U. pilulifera* in offering kidney protection through assessment of urea, uric acid and creatinine

## III. STUDY HYPOTHESIS

There is a body of existing literature pointing to the therapeutic potential of herbal treatments to decrease impacts of diabetes on kidneys through restoring kidney function tests (urea, uric acid and kidney) to levels approximate to reference ranges.

According to this context, it is hypothesized that *U. pilulifera*, a herbal treatment used by people to treat diabetes, will offer nephroprotective protection and lower the kidney function tests significantly as compared with control group.

## IV. METHODOLOGY

Methodology included collection of *U. pilulifera* and preparation of its extracts, induction of diabetic model and biochemical evaluation of urea, uric acid and creatinine tests.

### Collection of *U. pilulifera* and preparation of its extraction

*U. pilulifera* leaves were collected from appropriate areas at Jordan, air-dried in shade well-ventilated area and then ground into fine powder. About 350 g of powder was put in a Soxhlet cold extractor using absolute methanol as solvent and remained for three consecutive days (Sadki et al., 2001). The extract was concentrated to dryness in rotary evaporator under reduced pressure and controlled temperature (45°C) to yield an 11.4% viscous greenish-colored extract. The extract was kept at 4°C in a glass container until use. Wistar rats were used in this study, in which their average weight was 170 g. The animals were carefully checked and monitored every day for any changes. After determination of lethal dose (LD50), two doses were selected 1.25 g/kg and 1.88 g/kg of body weight. Doses were prepared through dissolving required amount of the viscous extract in 10 mL Tween-20: 0.9% NaCl (1:9, V/V).

### Diabetic model

Diabetes was induced employing alloxan so that rats were injected by alloxan monohydrate "B.O.H chemical LTD England" intraperitoneally at a dose of 150 mg/kg body weight (dissolved in fresh normal saline) to 18 hr fasted rat. Rats were monitored for blood glucose and rats with blood glucose level over 200 mg/dl, were considered diabetic and employed in the study. Animals were assigned into the following groups:

Group I: control group; Group II: diabetic group; Group III: diabetic treated with 1.25mg/kg of body weight; Group IV: diabetic treated with 1.88 mg/kg of body weight.

### Statistical analysis

Data analysis was carried out using SPSS 20. Data were presented as mean and standard deviation. T test was used to investigate the difference between kidney function tests in study groups. Significance level was considered at alpha level  $\leq 0.05$ .

## V. RESULTS

### The concentration of urea in study groups

As shown in table 1, the mean concentration of urea in control group was  $26.92 \pm 1.83$  mg/dl. The concentration of urea increased significantly ( $P < 0.05$ ) in diabetic group  $39.62 \pm 3.16$  mg/dl. Diabetic group that was treated with the extract of *U. pilulifera* (1.25 mg /kg) had significant decreased concentration of urea compared with diabetic group ( $25.52 \pm 1.62$  mg/dl;  $P < 0.05$ ). Treatment using higher dose of the extract of *U. pilulifera* also decreased the concentration of urea significantly compared with diabetic group ( $28.32 \pm 2.41$  mg/dl;  $P < 0.05$ ).

### The concentration of uric acid in study groups

As shown in table 1, the mean concentration of uric acid in control group was  $1.61 \pm 0.22$  mg/dl. The concentration of urea increased significantly ( $P < 0.05$ ) in diabetic group  $2.34 \pm 0.16$  mg/dl. Diabetic group that was treated with the extract of *U. pilulifera* (1.25 mg /kg) had significant decreased concentration of uric acid compared with diabetic group ( $1.42 \pm 0.06$  mg/dl;  $P < 0.05$ ). Treatment using a higher dose of the extract of *U. pilulifera* also decreased the concentration of uric acid significantly compared with diabetic group ( $1.62 \pm 0.12$  mg/dl;  $P < 0.05$ ).

### The concentration of creatinine in study groups

As shown in table 1, the mean concentration of creatinine in control group was  $0.98 \pm 0.08$  mg/dl. The concentration of creatinine increased significantly ( $P < 0.05$ ) in diabetic group  $2.16 \pm 0.12$  mg/dl. Diabetic group that was treated with the extract of *U. pilulifera* (1.25 mg /kg) had significant decreased concentration of creatinine compared with diabetic group ( $1.39 \pm 0.06$  mg/dl;  $P < 0.05$ ). Treatment using higher dose of the extract of *U. pilulifera* also decreased the concentration of creatinine significantly compared with diabetic group ( $1.26 \pm 0.14$  mg/dl;  $P < 0.05$ ).

Table 1: Concentration of Urea, Uric acid and Creatinine in study groups

Gr	Treatment	Urea (M $\pm$ SD) (mg/dl)	Uric acid (M $\pm$ SD) (mg/dl)	Creatinine (M $\pm$ SD) (mg/dl)
I	Control	26.92 $\pm$ 1.83	1.61 $\pm$ 0.22	0.98 $\pm$ 0.08
II	Diabetic (alloxan)	39.62 $\pm$ 3.16*	2.34 $\pm$ 0.16*	2.16 $\pm$ 0.12*
III	Treated group (1.25 mg/kg)	25.52 $\pm$ 1.62**	1.42 $\pm$ 0.06**	1.39 $\pm$ 0.06**
IV	Treated group (1.88 mg/kg)	28.32 $\pm$ 2.41**	1.62 $\pm$ 0.12**	1.26 $\pm$ 0.14**

## VI. DISCUSSION

We conducted the present study to investigate the effects of the extract of *U. pilulifera* on reducing the impacts of diabetes in kidneys. We depended on experimental diabetic model.

The data of the present study showed that all kidney function tests under study, urea, uric acid and creatinine were significantly ( $P < 0.05$ ) increased in diabetic group compared with control group. These findings are within the context of other studies in which it has been demonstrated that diabetic models were accompanied with increased levels of serum blood urea nitrogen (BUN) and serum uric acid (Piyachaturawat, Poprasit, Glinsukon, 1991; Asayama et al., 1994). It has also been reported that STZ displays nephrotoxic and necrosis of kidney tubules (Hasan et al., 1999).

The data of the present study demonstrated that treatment using the extract of *U. pilulifera* for one month was able to reverse the impacts of diabetes on kidneys of diabetic rats. Using either dose of *U. pilulifera* was able to restore all kidney function tests under study urea, uric acid and creatinine to levels approximate to normal levels. These variations among treated groups and diabetic groups were statistically significant ( $P < 0.05$ ). These findings are consistent with other studies in which various herbal treatments were used to treat diabetes and resulted in positive outcomes in improving kidney function tests. Gupta et al (2011) reported positive outcomes of kidney function tests by using *Momordica dioica*. Other researchers reported similar findings using *Olea europaea L*, *Gymnema montanum*, and *Annona squamosa* (Eidi et al., 2009; Ramkumar et al., 2009; Basha et al., 2011).

## VII. CONCLUSION

Experimental diabetic model showed negative impacts on kidney function tests urea, uric acid and creatinine. Using the extract of *U. pilulifera* showed significant restoring ability to restore kidney function tests to levels approximate to reference range. Taken together, the extract of *U. pilulifera* has a potential therapeutic option to be used in diabetic patients with renal impacts.

### Reference:

- [1] Asayama K, Nakane T, Uchida N, Hayashibe H, Dobashi K, Nakazawa S. Serum antioxidant status in streptozotocin-induced diabetic rat. *Horm Metab Res*. 1994 Jul;26(7) 313-315. doi:10.1055/s-2007-1001693. PMID: 7959605.
- [2] Bakris GL, Ritz E; World Kidney Day Steering Committee. The message for World Kidney Day 2009: hypertension and kidney disease: a marriage that should be prevented. *Clin J Am Soc Nephrol*. 2009 Mar;4(3):517-9. doi: 10.2215/CJN.00080109. Epub 2009 Feb 11. PMID: 19211670; PMCID: PMC4571533.
- [3] Salwe KJ, Sachdev DO, Bahurupi Y, Kumarappan M. Evaluation of antidiabetic, hypolipidemic and antioxidant activity of hydroalcoholic extract of leaves and fruit peel of *Punica granatum* in male Wistar albino rats. *J Nat Sci Biol Med*. 2015 Jan-Jun;6(1):56-62. doi: 10.4103/0976-9668.149085. PMID: 25810635; PMCID: PMC4367068.
- [4] Monika Sahu, Vinod Kumar, Veenu Joshi. Indian medicinal plants with antidiabetic potential: An overview. *Research Journal of Pharmacy and Technology*. 2021; 14(4):2328-5. doi: 10.52711/0974-360X.2021.00411
- [5] Eidi A, Eidi M, Darzi R. Antidiabetic effect of *Olea europaea L*. in normal and diabetic rats. *Phytother Res*. 2009 Mar;23(3):347-50. doi: 10.1002/ptr.2629. PMID: 18844257.
- [6] Gomathi D, Kalaiselvi M, Ravikumar G, Devaki K, Uma C. Evaluation of antioxidants in the kidney of streptozotocin induced diabetic rats. *Indian J Clin Biochem*. 2014 Apr;29(2):221-6. doi: 10.1007/s12291-013-0344-x. Epub 2013 May 28. PMID: 24757306; PMCID: PMC3990807.

- [7] Hasan. V., Günes., Irfan. Degirmenci., Miris. Aydin., Berrin. Bozan., Erinç. Aral., Zeynep. Tunalier., Cengiz. Üstüner., Murat. Erçakir., K. Hüsnü., C. Baser., Ayse. Basaran., (1999). The Effects of *Rumex patientia* L. and *Urtica dioica* L. on Some Blood and Urine Parameters, and Liver and Kidney Histology in Diabetic Rats. *Tr. J. of Medical Sciences*, 29, 227-232.
- [8] Jonasson. O., Jones. C.W., Bauman. A.B.S., John. E., Manaligod. J., Tso. M.O.M., (1984). The pathophysiology of experimental insulin-deficient diabetes in the monkey: implications for pancreatic transplantation. *Ann Surg*, 201:27-39.
- [9] NIDDK (National Institute of Diabetes and Digestive and Kidney Diseases)(2007). *Kidney diseases in diabetes*. 1, 8.
- [10] Patel. D.K., Kumar R., Prasad. S.K., Sairam. K., Hemalatha. S., (2011). Anti-diabetic and in vitro antioxidant potential of *Hybanthus enneaspermus* (Linn) F. Muell in streptozotocin-induced diabetic rats. *Asian Pac JTrop Biomed*, 1(4): 316-22.
- [11] Piyachaturawat. P., Poprasit. J., Glinsukon. T., (1991). Gastric mucosal secretions and lesions by different doses of streptozotocin in rats. *Toxicology Letters*, 55: 21-29.
- [12] Rajnish. Gupta., Katariya. P., Mathur. M., Bajaj V. K., Yadav, R. Kamal, R .S. Gupta S., (2011). Antidiabetic and renoprotective activity of *Momordica dioica* in diabetic rats. *Diabetologia Croatica*, 40-3
- [13] Ramkumar. K.M., Ponmanickam .P., Velayuthaprabhu.S., Archunan. G., Rajaguru. P., (2009). Protective effect of *Gymnema montanum* against renal damage in experimental diabetic rats. *Food Chem Toxicol*, 47:2516-2521.
- [14] Warjeet. Singh. L., (2011). Traditional medicinal plants of Manipur as anti-diabetics. *J Med Plants Res*, 5(5): 677-87.